

A pooled analysis of the resistance patterns of *Escherichia coli* strains isolated from urine cultures in Turkey: a comparison of the periods 1997-2001 and 2002-2007

Meltem İŞIKGÖZ TAŞBAKAN, Hüsnü PULLUKÇU, Oğuz Reşat ŞİPAHİ, Tansu YAMAZHAN,
Bilgin ARDA, Sercan ULUSOY

Aim: To compare the resistance patterns of *Escherichia coli* strains reported to be isolated from urine cultures in published medical literature from Turkey in 1997-2001 and 2002-September 2007.

Materials and methods: To find the published series, 3 national databases (Ulakbim Turkish Medical Literature database, <http://www.turkishmedline.com>, <http://medline.pleksus.com.tr>), and 2 international databases (Pubmed and Science Citation Index (SCI)) were searched.

Results: Data for 25,577 *E. coli* strains were obtained from 53 articles (28 articles from 1997-2001, 25 from 2002-2007). Of these strains 18,106 were isolated from outpatients, whereas 7471 were from inpatients. When the strains isolated from outpatients were evaluated, there was a significant increase in the ciprofloxacin resistance, whereas there was a significant decrease in amikacin, netilmicin, and co-trimoxazole resistance ($P < 0.05$). When the data of hospitalized patients were analyzed, there was significant decrease in amikacin, gentamicin, netilmicin, co-trimoxazole, and amoxicillin/clavulanate resistance, whereas a significant increase was observed in nitrofurantoin resistance ($P < 0.05$). The ESBL rate increased in both the inpatients and outpatients ($P < 0.05$).

Conclusion: When looked at from Turkey's perspective, our data suggest that aminoglycosides and third-generation cephalosporins may be good choices in the treatment of inpatients. Fosfomycin/tromethamine, nitrofurantoin, and oral third-generation cephalosporins may be reasonable alternatives in the empirical treatment of uncomplicated outpatient cases. Policies to constrain resistance in both the community, and hospitals, such as antibiotic stewardship or restriction programs, should be implemented immediately.

Key words: *E. coli*, Turkey, urinary tract infections

Türkiye'de idrar kültürlerinden izole edilen *Escherichia coli* kökenlerinde direnç durumlarının havuz analizi: 1997-2001 ve 2002-2007 dönemlerinin karşılaştırılması

Amaç: Bu çalışmada; 1997-2001 ve 2002- Eylül 2007 dönemlerinde Türkiye'de yapılmış olan yayınlardaki üriner sistem enfeksiyonlarından izole edilen *Escherichia coli* kökenlerinin direnç durumlarının karşılaştırılması amaçlanmıştır.

Yöntem ve gereç: Yayımlanmış olan makaleler üç ulusal veri tabanı (Ulakbim Türk Medikal Literatür veritabanı, <http://www.turkishmedline.com>, <http://medline.pleksus.com.tr>) ve iki uluslar arası (Pubmed and Science Citation Index) veri tabanında taranmıştır.

Bulgular: Toplam 53 makalede (1997-2001 döneminden 28 makale, 2002-2007 döneminden 25 makale) 25577 *E. coli* kökenine ait veriye ulaşılmıştır. Bu kökenlerden 18.106'sı poliklinik hastalarından, 7471'i yatan hastalardan izole

Received: 15.06.2010 – Accepted: 02.08.2010

Ege University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Bornova, İzmir - TURKEY

Correspondence: Meltem İŞIKGÖZ TAŞBAKAN, Ege University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Bornova, İzmir - TURKEY
E-mail: tasbakan@yahoo.com

edilmiştir. Poliklinik hastalarından izole edilen kökenler değerlendirildiğinde siprofloksasin direncinde önemli bir artış görülürken amikasin, gentamisin, netilmisin ve kotrimoksazol direncinde anlamlı bir azalma görülmüştür. Hastanede yatan hastaların verileri analiz edildiğinde amikasin, netilmisin, kotrimoksazol ve amoksisilin/klavulonat direncinde anlamlı azalma izlenirken, nitrofurantoin direncinde anlamlı bir artış gözlenmiştir.

Sonuç: Türkiye perspektifinden bakıldığında verilerimiz aminoglikozit ve üçüncü kuşak sefalosporinler yatan hastalarda iyi seçenekler olabileceğini düşündürmektedir. Komplike olmayan hastaların ampirik tedavisinde fosfomisin/trometamin, nitrofurantoin ve oral üçüncü kuşak sefalosporinler uygun alternatifler olabilir. GSBL oranı yatan hastalarda ve poliklinik hastalarında artmaktadır. Toplumda ve hastanede direnç oranlarını sınırlamak için antibiyotik yönetim politikaları ya da kısıtlama programları acilen uygulamaya konulmalıdır.

Anahtar sözcükler: *E. coli*, Türkiye, üriner sistem enfeksiyon

Introduction

Urinary tract infections (UTIs) are among the most common infectious diseases diagnosed in outpatients, and constitute the most common of nosocomial infections in many hospitals. *Escherichia coli* remains the principal causative pathogen of UTIs in both outpatients and inpatients (1). UTIs are also common indications for empirical antibiotic prescriptions. Trimethoprim/sulfamethoxazole, ciprofloxacin, semi-synthetic penicillins with or without inhibitors, nitrofurantoin, and fosfomycin tromethamine are the most commonly used antibacterial drugs in the treatment of community-acquired UTIs (2). Antimicrobial resistance is increasing in bacteria isolated from both nosocomial and community-acquired UTIs (3). Extended spectrum beta-lactamase (ESBL)-producing *E. coli* and *Klebsiella pneumoniae* are growing problems in many parts of the world (4,5).

The antimicrobial susceptibility of urinary pathogens has changed over the years and is influenced by such factors as the changing patient population and the extensive and inappropriate use of antimicrobial agents. Moreover, there are considerable geographic variations in bacterial patterns and resistance properties depending on local antimicrobial prescription practices. For these reasons, empirical antibiotic selection should be based on the knowledge of the local prevalence of bacterial organisms and antibiotic sensitivity patterns rather than on universal guidelines (6).

In this study, the aim was to analyze the resistance patterns of *E. coli* strains reported to be isolated from urine cultures in published medical literature between 1997 and September 2007 from Turkey.

Materials and methods

To find the published series, 3 national (Ulakbim Turkish Medical Literature database, <http://www.turkishmedline.com>, <http://medline.pleksus.com.tr>) and 2 international databases (Pubmed and Science Citation Index-Expanded (SCI-e)) were searched. Key words for the national databases were ["ıdrar yolu enfeksiyonu", "ıdrar yolu enfeksiyonu", "üriner sistem enfeksiyonu", "üriner sistem enfeksiyonu", or "urinary tract infection"]. Key words for Index Medicus and SCI were ["urinary tract infection" and "Turkey"]. In cases of presentations from a single study with intersecting periods, the one covering a longer period was chosen. Articles published before 1997 were excluded. In all studies, isolated bacteria were identified by standard laboratory techniques, and antibiotic susceptibility tests were performed by Kirby-Bauer disc diffusion method according to the National Committee for Clinical Laboratory Standards (NCCLS), and Clinical Laboratory Standards Institution (CLSI) criteria (7).

Resistance data of strains isolated from outpatients and hospitalized patients were evaluated separately. All data were analyzed with SPSS for Windows, version 13.00. Pooled resistance data of strains related to 1997-2001, and 2001-2007 were compared using the chi-square test. A P value less than 0.05 was considered significant.

Results

Our search yielded 53 articles (28 articles from 1997-2001, 25 from 2002-2007), which consisted of a total of 25,577 *E. coli* strains. Of these 25,577, 18,106

were isolated from outpatients, whereas 7471 were isolated from inpatients (1-3,8-57). A comparison of resistance rates of strains isolated from outpatients and inpatients is shown in Tables 1 and 2.

When the strains isolated from outpatients were evaluated, there was a significant increase in gentamicin and ciprofloxacin resistance, whereas there was a significant decrease in amikacin, netilmicin, and co-trimoxazole resistance. There was no significant difference for nitrofurantoin between the 2 periods. There was a decrease in amoxicillin/clavulanate and piperacillin/tazobactam resistances, and carbapenem resistance rates were low in both of the 2 periods (2.3% vs 1%).

When data of hospitalized patients were analyzed, there was significant decrease in amikacin, gentamicin, netilmicin, co-trimoxazole, and amoxicillin/clavulanate resistance, whereas a significant increase was observed in nitrofurantoin. Overall carbapenem resistance was low in the hospitalized cases as well (2.3% vs. 0.8%).

Discussion

E. coli is the most common aetiological agent in either community-acquired or hospital acquired UTI. The increasing prevalence of infections caused by antibiotic resistant *E. coli* makes empirical treatment of these infections more difficult (58). Hence, there exists a great need for antimicrobial resistance surveillance at the local, national, and international levels (59).

Our data suggest that aminoglycosides are still important in the empirical treatment of UTIs. Pooled data of 10 years in outpatients and inpatients yielded amikacin resistance rates of 6.1% and 6.8%, respectively. When 1997-2001 and 2002-2007 were compared, the resistant rates decreased significantly in both groups. While Puerto et al. (60) and Alhambra et al. (61) did not report amikacin resistant strains from Spain, Hernandez et al. (62) reported a resistance rate of 6.5% in ESBL-producing strains. Our results are similar to those of other Mediterranean countries. We may speculate that the decrease in aminoglycoside resistance may be because of probable low empirical therapy consumption rates, due to toxicity, obligatory use of parenteral route, and the narrow spectrum of this class.

Ciprofloxacin is among the most widely used agents in outpatient urinary tract cases due to its high bioavailability, concentration in the urinary system, and antibacterial spectrum (66). It is also a widely used agent in diarrhea and intra-abdominal infections. Resistance to ciprofloxacin was found to be 20.1% in outpatients and 31.7% in inpatients. When compared with 1997-2001, ciprofloxacin resistance increased significantly in both inpatients and outpatients in 2002-2007. This may be associated with the following: i) oral ciprofloxacin is widely used without any restriction, or ii) increasing ESBL rates, since ESBLs are often located on plasmids, which also carry QNR determinants (67). In studies carried out in Turkey, the quinolone resistance was found to be between 2.1% and 44.2% in community acquired UTIs (24,51). In studies reported from various countries, there were variable resistance rates. Marchese et al. reported a 12% ciprofloxacin resistance in *E. coli* strains isolated as UTI pathogens (68). Puerto et al., in a region experiencing a resistance problem from Spain, reported high resistance rates similar to our results (60). In a Brazilian multicenter study, ciprofloxacin resistance was reported to be 21.6% (64). Ciprofloxacin is one of the most important agents in the treatment of UTIs, but regional resistance rates should be kept in mind when using this agent in empirical therapy.

Nitrofurantoin resistance rates were similar in outpatients in 1997-2001 and 2002-2007. However, in inpatients there was a significant increase in 2002-2007. Resistance rates of nitrofurantoin reported from developing countries range between 6.9% and 31.6% (63-65,69). Rates such as 6.2% from Spain (70) and 3.7% from the UK (71) are also reported. Nitrofurantoin has been used for a very long time for the treatment of UTIs; however, the introduction of ciprofloxacin to the market has limited its consumption. The fact that nitrofurantoin is effective in both in vitro and clinical studies against ESBL and *E. coli* suggests that it may be an important and economical treatment option in the near future (44,72,73). Although non-significant, the decrease in nitrofurantoin resistance among strains isolated from outpatients strengthens this hypothesis, and suggests that it may be a reasonable choice in the empirical treatment of UTIs.

Table 1. The resistance rates of *E. coli* strains isolated from outpatients.

	1997-2001 % (Resistant/n)	2002-2007 % (Resistant/n)	Total % (Resistant/n)	P
Gentamicin	11.6 (822/7073)	16.6 (774/4671)	13.6 (1596/11744)	0.0001
Amikacin	8.2 (387/4736)	3 (96/3224)	6.1 (483/7960)	0.0001
Netilmicin	7.2 (127/1743)	3.8 (128/3296)	5 (255/5039)	0.0001
Ciprofloxacin	16.6 (1353/8149)	24.1 (1705/7072)	20.1 (3058/15221)	0.0001
Nitrofurantoin	20 (558/2785)	18.4 (624/3397)	19.1 (1182/6182)	0.097
Co-trimoxazole	48.5 (4631/9543)	45.4 (3626/7990)	47.1 (8257/17533)	0.0001
Ceftriaxone	9.3 (588/6325)	8.3 (279/3366)	8.9 (867/9691)	0.098
Cefuroxime	16.3 (757/4636)	20.6 (999/4843)	18.5 (1756/9479)	0.0001
Amoxicillin/clavulanate	37.7 (1192/3159)	24.4 (1321/4812)	31.5 (2513/7971)	0.0001
Piperacillin/tazobactam	12.5 (54/430)	8.2 (171/2077)	9 (225/2507)	0.004
Imipenem	2.3 (65/2822)	0.07 (3/4182)	1 (68/7004)	0.0001
ESBL	8 (36/450)	13.1 (333/2534)	12.4 (369/2984)	0.002

Trimethoprim-sulfamethoxazole is an agent that has been used in the treatment of UTIs for a very long period, even before quinolones entered the market (5). In our study, resistance to co-trimoxazole was found to be 47.1% in outpatients, and 52.4% in inpatients. The resistance rates to this agent decreased significantly in 2002-2007. The probable reason for decreased usage was the high resistance rates, which might have contributed to this situation. However, the rates being still very high, co-trimoxazole cannot be recommended in the empirical therapy of UTIs. Co-trimoxazole resistance is high in almost every part of the world (74,75). Ungheri et al. reported co-trimoxazole resistance in strains resistant to

quinolones as 48.1% (76). In the study by Puerto et al., there was a co-trimoxazole resistance rate of 49.3%, which is similar to our rates (60).

When compared with other European countries, cephalosporin resistance in *E. coli* may be considered high (61,63). Especially resistance to cefuroxime was found to have increased significantly in outpatients. Ceftriaxone may be preferred in cases of failure with first line drugs, or infections with resistant strains. Resistance to β -lactam- β lactamase inhibitors is high, except piperacillin/tazobactam. Hence, empirical usage cannot be recommended without antibiotic susceptibility results.

Table 2. The resistance rates of *E. coli* strains isolated from hospitalized patients.

	1997-2001 % (Resistant/n)	2002-2007 % (Resistant/n)	TOTAL % (Resistant/n)	P
Gentamicin	24.5 (533/2177)	18.3 (432/2358)	21.3 (965/4535)	0.0001
Amikacin	10.7 (222/2072)	2.7 (52/1953)	6.8 (274/4025)	0.0001
Netilmicin	11.8 (39/330)	5.7 (120/2107)	6.5 (159/2437)	0.0001
Ciprofloxacin	30.9 (989/3199)	32.4 (1312/4051)	31.7 (2301/7250)	0.52
Nitrofurantoin	15.5 (153/989)	19.8 (297/1497)	18.1 (450/2486)	0.006
Co-trimoxazole	56 (1845/3295)	48.7 (1973/4051)	52.4 (3848/7346)	0.0001
Ceftriaxone	15.7 (503/3210)	15 (316/2104)	15.4 (819/5314)	0.521
Cefuroxime	28.4 (440/1551)	27.1 (695/2565)	27.6 (1135/4116)	0.376
Amoxicillin/clavulanate	52.8 (716/1355)	31.5 (827/2628)	38.7 (1543/3983)	0.0001
Piperacillin/tazobactam	8.3 (8/96)	12.2 (155/1272)	11.9 (163/1368)	0.261
Imipenem	2.3 (65/2787)	0.8 (24/3077)	1.5 (89/5864)	0.0001
ESBL	13.7 (19/139)	20 (376/1880)	19.6 (395/2019)	0.069

Reports from Turkey suggest that ESBL-producing *E. coli* is increasing. The treatment of cases infected with these bacteria is challenging. Sparing carbapenems for the treatment of these cases may be a rational approach (73).

This study comprised pooled resistance data of 25,577 urinary tract infection related *E. coli* strains published between 1997 and 2007. The main limitations of our study were: i) resistance data of all antibiotics were not provided in all studies and so data were not homogeneous, ii) analyzed studies comprised retrospectively retracted data, iii) we cannot exclude some of the strains that were not reported from more than one center, iv) patient

groups were mostly classified as inpatients and outpatients in the articles. There was no classification as to healthcare associated infections. Hence, some of the inpatients or outpatients might be healthcare-associated infections.

Despite these disadvantages, this study provides the largest available data regarding the issue and enlightens future studies.

The Infectious Diseases Society of America guidelines suggest being cautious when using an antibiotic in empirical therapy, when resistance to it exceeds 20% (59). In light of our data, which give a global Turkish perspective, it is not rational to

offer quinolones, co-trimoxazole, and beta-lactams (except third-generation cephalosporins) in the empirical treatment of UTIs. Aminoglycosides and third-generation cephalosporins may be good choices in the treatment of inpatients. Fosfomycin, nitrofurantoin, and oral third-generation cephalosporins may be reasonable alternatives in the empirical treatment of uncomplicated cases. Quinolones and co-trimoxazole should be used only in cases with culture results showing specific sensitivity. Carbapenems should be conserved

for extended-spectrum beta lactamase producing strains. Our data suggest that the ESBL-producer *E. coli* rate in the outpatient strains is alarming. Policies to constrain resistance in both the community and hospital, such as antibiotic stewardship or restriction programs, should be implemented immediately. Finally, we may recommend making a discrimination of healthcare-associated infections in strains isolated from inpatients and outpatients in future studies. This will help us to accumulate more accurate data about the issue.

References

1. Karaca Y, Çoplu N, Gozalan A, Oncul O, Cital B, Esen B. Co-trimoxazole and quinolone resistance in *Escherichia coli* isolated from urinary tract infections over the last 10 years. *Int J Antimicrob Agents* 2005; 26: 75-7.
2. Arslan H, Azap KÖ, Ergönül Ö, Timurkaynak F. Risk factors for ciprofloxacin resistance among *Escherichia coli* strains isolated from community-acquired urinary tract infections in Turkey. *J Antimicrob Chemother* 2005; 56: 914-8.
3. Pullukcu H, Tasbakan MI, Aydemir Ş, Sipahi OR, Turhan A, Özinel MA et al. The bacteria isolated from urine cultures and their in- vitro antibiotic susceptibility. *ANKEM Derg* 2006; 20: 26-30.
4. Sturenburg E and Mack D. Extended spectrum beta-lactamases. Implications for the clinical microbiology laboratory, therapy and infection control. *J Infect* 2003; 47: 273-95.
5. Pullukcu, H, Aydemir S, Tasbakan MI, Çilli F, Tunger A, Ulusoy S. Susceptibility of extended-spectrum beta-lactamase producing *Escherichia coli* urine isolates to fosfomycin, ciprofloxacin, amikacin and trimethoprim sulfamethoxazole. *Turk J Med Sci* 2008; 38: 175-180.
6. Yüksel S, Öztürk B, Kavaz A, Özçakar ZB, Acar B, Güriz H et al. Antibiotic resistance of urinary tract pathogens and evaluation of empirical treatment in Turkish children with urinary tract infections. *Int J Antimicrob Agents* 2006; 28: 413-6.
7. Clinical and Laboratory Standards Institute/NCCLS: Performance Standards for Antimicrobial Susceptibility Testing. 15. Informational Supplement, CLSI/NCCLS, M100-S15, Wayne: PA; 2005.
8. Yuluğkural Z, Mutlu B. Susceptibility of *Escherichia coli* strains isolated from urine cultures to some commonly used antibacterial agents *Medical Journal of Trakya University* 2007; 24: 6-11.
9. Yılmaz E, Özakin C, Sınırtaş M, Gedikoğlu S. Microorganisms isolated from urine specimens in the bacteriology laboratory, Uludağ University Hospital, between 1999 and 2002. *Turkish Journal of Infection* 2005; 19: 91- 6.
10. Ertuğrul MB, Çolak N. Antibiotic susceptibility rates of community-acquired uropathogenic *Escherichia coli* isolates. *ANKEM Derg* 2004; 18: 161-5.
11. Taşbakan MI, Pullukçu H, Yamazhan T, Arda B, Ulusoy S. Comparison of in-vitro activity of fosfomycin and other antibacterials in *Escherichia coli* strains isolated from community acquired urinary tract infections. *ANKEM Derg* 2004; 18: 216-219.
12. Bayraktar B, Özcan N, Borahan S, Başarı F, Bulut E. Resistance in Gram negative bacilli isolated from urinary tract infections in hospitalized and polyclinic patients *ANKEM Derg* 2004; 18: 137-140.
13. Saraçlı MA, Baylan O, Gün H. Gram negative bacilli causing urinary tract infections and their antibiotic susceptibilities. *ANKEM Derg* 1999; 13: 73-78.
14. Kaygusuz S, Apan TZ, Kılıç D. Resistance to various antibiotics of Gram-negative bacteria isolated from community-acquired urinary tract infections. *ANKEM Derg* 2001; 15: 753-9.
15. Erden S, Çalangu S. Poliklinik hastalarında üriner sistem infeksiyonlarından izole edilen *Escherichia coli* suşlarının çeşitli antibiyotiklere in vitro duyarlılıkları. *İst Tıp Fak Mecmuası* 2002; 65: 147-149.
16. Özden M, Kalkan A, Demirdağ K, Kılıç SS, Özdarendeli A. Ciprofloxacin and co-trimoxazole resistance in *Escherichia coli* strains isolated from urinary tract infections. *ANKEM Derg* 2003; 17: 51-55.
17. Ağel E, Durmaz B, Kutlu O, Balat A, Aşgın N. Antimicrobial activity of loracarbef and its efficiency in pediatric patients with urinary tract infections. *ANKEM Derg* 2000; 14: 79-84.
18. Cesur S, Albayrak F, Özdemir D, Kolcu Z, Tekeli E. Antibiotic susceptibilities of Gram negative rods isolated from urine samples obtained from hospitalized patients. *Türk Mikrobiyol Cem Derg* 2002; 33: 174-6.
19. Demirtürk N, Demirdal T, Eldemir H, İnce R, Altunış M. Bacteria isolated from urine samples and their antibiotic susceptibilities. *Türk Mikrobiyol Cem Derg* 2005; 35: 103-6.
20. Kurutepe S, Sürücüoğlu S, Sezgin C, Gazi H, Gulay M, Özbakkaloğlu B. Increasing antimicrobial resistance in *Escherichia coli* isolated from community-acquired urinary tract infections during 1998-2003 in Manisa, Turkey. *Jpn J Infect Dis* 2005; 58: 159-161.

21. Otağ F, Yıldız Ç, Delialioğlu N. Antibiotic resistance of *Escherichia coli* strains isolated from urine samples. ANKEM Derg 2003; 17: 384-7.
22. Baykan M, Kaya M, Arslan U, Baysal B. Sensitivity of antimicrobics to *E. coli* strains isolated from urine samples. İnönü Üniversitesi Tıp Fakültesi Dergisi 2001; 8: 15-7.
23. Aydos SE, Yavuzdemir Ş, Nohutçu Y, Çavuş İ. In vitro sensitivity of bacteria to various antibiotics, obtained from women suffering from cystitis. Türk Jinekoloji ve Obstetrik Derneği Dergisi 2006; 3: 118-21.
24. Özkalp B, Topçu A. The Gram negative bacteria those isolated from urinary tract infections and their susceptibility to various antibiotics. Selçuk Üniversitesi Tıp Fakültesi Dergisi 2000; 16: 171-4.
25. Çetin H, Öktem F, Örmeci AR, Yorgancıgil B, Yaylı G. *Escherichia coli* and antibiotic resistance in childhood urinary tract infections. Süleyman Demirel Üniversitesi Tıp Fak Derg 2006; 13: 12-6.
26. İnan UN, Gürler N. Investigation of antibiotic resistance and some virulence factors of *Escherichia coli* strains isolated from children with urinary tract infections. ANKEM Derg 2004; 18: 89-96.
27. Gürgöze MK, Doğan Y, Kizirgil A, Toraman ZA, Aygün D. Antibiotic sensitivities of bacteria isolated from children with urinary tract infections. Fırat Tıp Dergisi 2002; 7: 828-832.
28. Gündüz T, Mumcuoğlu İ. Antimicrobial susceptibility of *Escherichia coli* strains isolated from urine samples. Türk Mikrobiyol Cem Derg 2004; 34: 157-161.
29. Elaldı N, Turan M, Duran B, Bakır M, Dökmetaş İ, Bakıcı MZ, Şahin F. Nosocomial urinary tract infections in a university hospital: Causative microorganisms and antimicrobial resistance. Cumhuriyet Üniversitesi Tıp Fakültesi Dergisi 2003; 25: 63-8.
30. Demirci M, Arıdoğan BC, Arda M. Antibiotic sensitivity of gram negative bacilli isolated from outpatients urine cultures. ANKEM Derg 2000; 14: 576-9.
31. Taşova Y, Saltoğlu N, Yaman A, Yılmaz G, Dündar İH. Nosocomial urinary tract infections in the Medical Faculty Hospital, Çukurova University. Turkish J Infect 1999; 13: 249-254.
32. Erdem H, Avcı A, Pahsa A. The Antibacterial resistance in community acquired uropathogenic *Escherichia coli* strains. ANKEM Derg 2004; 18: 40-4.
33. Akan ÖA. Antibiotic Resistance of urinary *Escherichia coli* isolated from outpatient samples against first line drugs. Ankara Üniversitesi Tıp Fakültesi Mecmuası 2003; 56: 147-50.
34. Sucu N, Boz GA, Bayraktar Ö, Çaylan R, Aydın K, Köksal İ. The change of antibiotic susceptibilities of uropathogen *Escherichia coli* strains in years. Klimik Dergisi 2004; 17: 128-131.
35. Tolun V, Akbulut DT, Çatal Ç, Turan N, Küçükler MA, Ang Ö. The antibiotic susceptibilities of gram negative rods isolated as causative agents of urinary tract infections from in- and outpatients. Türk Mikrobiyol Cem Derg 2002; 32: 69-74.
36. Eroğlu C, Günaydın M, Birinci A, Esen Ş, Sünbül M, Leblebicioğlu H. determination of extended spectrum beta lactamases (ESBL) in *Escherichia coli* strains isolated from urinary system infections. Turk Mikrobiyol Cem Derg 2003; 33: 118-121.
37. Kibar F, Yaman A, Dündar İH. Bacteria isolated from urine samples and their antibiotic susceptibilities. Turk Mikrobiyol Cem Derg 2004; 34: 162-170.
38. Çitil BE, Çöplü N, Gözalan A, Öncül Ö, Karaca Y, Esen B. The evaluation of antibiotic resistance in urinary tract infection agent *Enterobacteriaceae* spp. for two years. The Medical Journal of Kocatepe 2006; 7: 31-5.
39. Şencan İ, Sevinç ME. Antimicrobial resistance survey of community-acquired uropathogen *Escherichia coli* isolated. Klimik Dergisi 2002; 15: 85-8.
40. Altındiş M, Tanır HM. Microbiological evaluation of urine samples taken from patients with urinary tract infections symptoms and susceptibilities to various antibiotic against of the gram-negative microorganisms isolated from those women. Türk Mikrobiyol Cem Derg 2001; 31: 192-7.
41. Savaş L, Güvel S, Turunç T, Savaş N, Arslan H. Comparison of the causative microorganisms and their antibiotic susceptibility between community acquired and nosocomial urinary tract infections. Türk Üroloji Dergisi 2003; 29: 95-100.
42. Ertuğrul MB, Güleç LA, Akal D, Çagatay AA, Özüt H, Eraksoy H, Çalangu S. Susceptibility of uropathogen *Escherichia coli* isolates to the antimicrobials used commonly in urinary tract infections. Klimik Dergisi 2004; 17: 132-6.
43. Tünger Ö, Sürücüoğlu S, Özbakkaloğlu B, Gazi H. Extended spectrum beta lactamase production and susceptibility to antibiotics in *Escherichia coli* strains isolated from community acquired and nosocomial infections. Mikrobiyol Bül 2001; 35: 351-7.
44. Pullukçu H, Aydemir Ş, Taşbakan Mİ, Sipahi OR, Çilli F, Ulusoy S. In vitro efficacy of nitrofurantoin *Escherichia coli* strains isolated from urine cultures. Turk J Infect 2007; 21: 197-200.
45. Gazi H, Sürücüoğlu S, Kurutepe S. Antimicrobial resistance of Gram Negative bacteria isolated from urine cultures. ANKEM Derg 2007; 21: 19-22.
46. Koçoğlu E, Karabay O, İnce NK, Özkardeş F, Yıldırım R. The frequency of extended spectrum beta-lactamase production and antibiotic susceptibility of *Escherichia coli* strains isolated from community-acquired urinary tract infections. ANKEM Derg 2007; 21: 5-9.
47. Turunç T, Turunç T. Nosocomial urinary tract infections related with urinary catheter in patients from intensive care units. Türk Üroloji Dergisi 2003; 29: 209-14.
48. Ay S, İşeri LA, Duman B. Antibiotic Susceptibilities of Gram Negative microorganisms isolated from urine samples. İnönü Üniversitesi Tıp Fakültesi Dergisi 2003; 10: 59-62.
49. Şahin İ, Öksüz Ş, Kaya D, Şencan İ, Gülcan A. Antibiotic susceptibility of uropathogenic Gram Negative rods isolated from inpatient and outpatient children. ANKEM Derg 2004; 18: 101-104.
50. Yetkin G, Kuzucu Ç, Çalışkan A. An investigation on *Escherichia coli* strains with extended spectrum beta lactamase growth in urinary cultures. İnönü Üniversitesi Tıp Fakültesi Dergisi 2006; 13: 249-252.

51. Arca AE, Karabiber N. Short Communication: Comparison of susceptibilities of *Escherichia coli* urinary tract isolates against fosfomycin tromethamine and different antibiotics. *Microbiyol Bült* 2007; 41: 115-119.
52. Gulsun S, Oğuzoğlu N, Ceran N, İnan A, Göktaş P. The virulence factors and antibiotic sensitivities of *Escherichia coli* strains isolated from recurrent urinary tract infections. *Saudi Med J* 2005; 26: 1755-8.
53. Öktem MA, Gülay Z, Ercan H, Biçmen M, Yuluğ N. Microorganisms isolated in intensive care units and their antibiotic susceptibility. *Turk J Infect* 2001; 15: 61-66.
54. Timurkaynak F, İnci EK, Arslan H. Characteristics and antibiotic susceptibility of pathogens isolated from community acquired and nosocomial urinary tract infections. *Ankara Üniversitesi Tıp Fakültesi Mecmuası* 2001; 54: 287-292.
55. Aral M, Çıragil P, Gül M, Ekerbiçer HÇ, Çelik M, Koçtürk SA. The spectrum of bacteria isolated from urinary tract infections in children aged 0-5 years and antibiotic resistance status of Gram Negative bacteria. *Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi* 2005; 2: 5-9.
56. Şener A, Yapar N, Çakır N, Yüce A. Searching asymptomatic bacteriuria in Yeşilyurt nursery home geriatric residents and susceptibility patterns of bacteria. *Medical Journal of İzmir Hospital* 2004; 10: 69-71.
57. Sümer Z, Çoşkun C, Vahaboglu H, Bakır M. The resistance of *Escherichia coli* strains isolated from community-acquired urinary tract infections. *Adv Ther* 2005; 22: 419-23.
58. Ozyurt M, Haznedaroğlu T, Sahiner F, Oncül O, Ceylan S, Ardiç N, Erdemoğlu A. Antimicrobial resistance profiles of community-acquired uropathogenic *Escherichia coli* isolates during 2004-2006 in a training hospital in İstanbul *Mikrobiyol Bul* 2008; 42: 231-43.
59. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. *Clin Infect Dis* 1999; 29: 745-58.
60. Puerto AS, Fernández JG, del Castillo Jde D, Pino MJ, Angulo GP. In vitro activity of beta-lactam and non-beta-lactam antibiotics in extended-spectrum beta-lactamase-producing clinical isolates of *Escherichia coli*. *Diagn Microbiol Infect Dis* 2006; 54: 135-9.
61. Alhambra A, Cuadrs JA, Cacho J, Gómez-Garcés JL, Alós JI. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. *J Antimicrob Chemother* 2004; 53: 1090-4.
62. Hernández JR, Martínez-Martínez L, Cantón R, Coque TM, Pascual A. Spanish Group for Nosocomial Infections (GEIH). Nationwide study of *Escherichia coli* and *Klebsiella pneumoniae* producing extended-spectrum beta-lactamases in Spain. *Antimicrob Agents Chemother*. 2005; 49: 2122-5.
63. Kamberovic SU. Antibiotic resistance of coliform organisms from community-acquired urinary tract infections in Zenica-Doboj Canton, Bosnia and Herzegovina. *JAC* 2006; 58: 344-8.
64. Andrade SS, Sader HS, Jones RN, Pereira AS, Pignatari AC, Gales AC. Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin America: time for local guidelines? *Mem Inst Oswaldo Cruz*. 2006; 101: 741-8.
65. Akram M, Shahid M, Khan AU. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India. *Ann Clin Microbiol Antimicrob* 2007; 6: 4.
66. Canbaz S, Peksen Y, Tevfik Sunter A, Leblebicioglu H, Sunbul M. Antibiotic prescribing and urinary tract infection. *Int J Antimicrob Agents*. 2002; 20: 407-11.
67. Nordmann P, Poirel L. Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. *J Antimicrob Chemother* 2005; 56: 463-9.
68. Marchese A, Gualco L, Debbia EA, Schito GC, Schito AM. In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance. *Int J Antimicrob Agents*. 2003; 22 Suppl 2: 53-9
69. Das RN, Chandrashekar TS, Joshi HS, Gurung M, Shrestha N, Shivananda PG. Frequency and susceptibility profile of pathogens causing urinary tract infections at a tertiary care hospital in western Nepal. *Singapore Med J*. 2006; 47: 281-5.
70. Gobernado M, Valdés L, Alós JI, García-Rey C, Dal-Ré R, García-de-Lomas J; Spanish Surveillance Group for Urinary Pathogens. Antimicrobial susceptibility of clinical *Escherichia coli* isolates from uncomplicated cystitis in women over a 1-year period in Spain. *Rev Esp Quimioter* 2007; 20: 68-76.
71. Farrell DJ, Morrissey I, De Rubeis D, Robbins M, Felmingham D. A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection. *J Infect* 2003; 46: 94-100.
72. Tasbakan M, Pullukcu H, Sipahi O, Yamazhan T, Ulusoy S. Nitrofurantoin In the treatment of Extended-Spectrum Beta-Lactamase (ESBL) Producing *E. coli* related lower urinary tract infection (luti). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, 46th Infectious Diseases Society of America Annual Meeting. Washington, poster L494.
73. Sipahi OR. Economics of antibiotic resistance. *Exp Rev Anti-Infect Ther* 2008; 6: 523-539.
74. Talan DA, Krishnadasan A, Abrahamian FM, Stamm WE, Moran GJ. EMERGENCY ID NET Study Group. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant *Escherichia coli* infection among emergency department patients with pyelonephritis. *Clin Infect Dis* 2008; 47:1150-8.
75. Guajardo-Lara CE, González-Martínez PM, Ayala-Gaytán JJ. Antibiotic resistance of *Escherichia coli* from community-acquired urinary tract infections. What antimicrobial to use? *Salud Publica Mex*. 2009; 51: 155-9.
76. Ungheri D, Albini E, Belluco G. In-vitro susceptibility of quinolone-resistant clinical isolates of *Escherichia coli* to fosfomycin trometamol. *J Chemother*. 2002; 14: 237-40.
77. Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir Ş, Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing *Escherichia coli*-related lower urinary tract infections. *Int J Antimicrob Agents* 2007; 29: 62-65.